$CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma$

CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) exhibits frequent inactivating mutations of the histone acetyltransferase CREBBP, highlighting the attractiveness of targeting CREBBP deficiency as a therapeutic strategy. In this study, we demonstrate that chidamide, a novel histone deacetylase (HDAC) inhibitor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2021-11, Vol.521, p.268-280
Hauptverfasser:	Sun, Yichen, Gao, Yan, Chen, Jianfeng, Huang, Ling, Deng, Peng, Chen, Jinghong, Chai, Kelila Xin Ye, Hong, Jing Han, Chan, Jason Yongsheng, He, Haixia, Wang, Yali, Cheah, Daryl, Lim, Jing Quan, Chia, Burton Kuan Hui, Huang, Dachuan, Liu, Lizhen, Liu, Shini, Wang, Xiaoxiao, Teng, Yan, Pang, Diwen, Grigoropoulos, Nicholas Francis, Teh, Bin Tean, Yu, Qiang, Lim, Soon Thye, Li, Wenyu, Ong, Choon Kiat, Huang, Huiqiang, Tan, Jing
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitumor activity B-cell lymphoma Biomarkers Cancer therapies Cell cycle Cell growth Chidamide Clinical trials CREBBP DLBCL Drug screening Epigenetics Experiments Histone acetyltransferase Histone deacetylase Lymphocytes B Lymphoma Mutation Patients Plasmids Resistance Software
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!